Combining olaparib and temozolomide in uterine leiomyosarcoma: a promising synergy скачать в хорошем качестве

Combining olaparib and temozolomide in uterine leiomyosarcoma: a promising synergy

Brian van Tine, MD, PhD, Washington University, St. Louis, MO, comments on the rationale behind combining olaparib with temozolomide in advanced uterine leiomyosarcoma, citing preclinical data showing synergy between PARP inhibitors and temozolomide in models with BRCA1 and BRCA2 mutations. Dr van Tine notes that this combination has shown promise in a Phase II trial (NCT03880019, with a 30% response rate, and is now being explored in a larger trial. He suggests that this approach may have broader applications in other sarcoma histologies, particularly those with underlying genetic mutations that affect homologous recombination repair. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.